Transcutaneous Diaphragm Stimulation in ICU Patients
ConditionIntensive Care Patients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorKaradeniz Technical University
About this trial
The aim of this study is to compare the effects of transcutaneous electrical diaphragm stimulation (TEDS) on diaphragm thickness, duration of mechanical ventilation, length of ICU stay, and right/left heart functions between patient groups with low and high ejection fraction (EF) levels.
This randomized controlled trial will record demographic data, diaphragm ultrasound measurements, and echocardiographic findings of patients who receive or do not receive TEDS for five consecutive days.
Participants will be divided into four groups according to their EF levels and whether or not they receive diaphragm stimulation:
Group 1: Patients with low EF who receive TEDS Group 2: Patients with high EF who receive TEDS Group 3: Patients with low EF who do not receive TEDS Group 4: Patients with high EF who do not receive TEDS
Diaphragm thickness and echocardiographic assessments will be performed at baseline and at the end of the five-day TEDS intervention.
TEDS Application Protocol
In the ICU, TEDS is administered by a physiotherapist once daily for 20 minutes, five days a week, as part of the routine treatment protocol. The stimulation is delivered using the LGT-231 model device from the LONGEST brand.
A transcutaneous current with a frequency of 30-50 Hz and a pulse width of 300-400 microseconds is applied to the diaphragm. The stimulation intensity is increased until visible muscle contraction is achieved.
Electrode placement involves:
The first pair of electrodes placed bilaterally between the 8th and 10th anterior intercostal spaces, lateral to the xiphoid process.
The second pair placed along the mid-axillary line of the thorax, also between the 8th and 10th intercostal spaces.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged between 18 and 80 years
Patients expected to require mechanical ventilation for at least 72 hours
Disqualifiers
Presence of known neuromuscular diseases that contraindicate the use of transcutaneous diaphragm stimulation
Phrenic nerve injury
History of abdominal or thoracic surgery that prevents the application of diaphragm stimulation
Trial design
Design model
Parallel
Treatments tested in this trial
Transcutaneous Diaphragm Stimulation
DeviceIn the ICU, TEDS is administered by a physiotherapist once daily for 20 minutes, five days a week, as part of the routine treatment protocol. The stimulation is delivered using the LGT-231 model device from the LONGEST brand. A transcutaneous current with a frequency of 30-50 Hz and a pulse width of 300-400 microseconds is applied to the diaphragm. The stimulation intensity is increased until visible muscle contraction is achieved.
Treatment groups
76 Participants
are divided into 4 treatment groupsGroup A: Group 1: Patients with low EF who receive TEDSExperimental treatment 1 intervention
Group B: Group 2: Patients with high EF who receive TEDSExperimental treatment 1 intervention
Group C: Group 3: Patients with low EF who do not receive TEDSNo intervention 0 interventions
Group D: Group 4: Patients with high EF who do not receive TEDSNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Diaphragm Thickness and Thickening Fraction Measured by Ultrasound
Diaphragm thickness will be measured using B-mode ultrasonography. The following parameters will be assessed: Diaphragm thickness at end-expiration (Tdi-exp), in millimeters (mm) Diaphragm thickness at end-inspiration (Tdi-insp), in millimeters (mm) Diaphragm thickening fraction (TF), calculated using the following formula: TF = (Tdi-insp - Tdi-exp) / Tdi-exp × 100.
Time frame
At baseline (Day 0) and on Day 5 of the study2
Duration of mechanical ventilation
Length of ICU stay will be recorded in days for each patient during the 5-day study follow-up. The duration will be calculated from the date and time of ICU admission until discharge or the end of the 5-day observation period, whichever comes first. Data will be obtained from patient medical records.
Time frame
At the beginning of the study and at the end of the 5-day period3
Length of stay in the intensive care unit
The total number of days each patient remains in the intensive care unit (ICU) will be recorded during the 5-day follow-up period. ICU stay duration will be calculated from the time of ICU admission until ICU discharge or the end of the 5-day observation period, whichever occurs first. Data will be obtained from patient medical records.
Time frame
At the beginning of the study and at the end of the 5-day period4
Cardiac Function Parameters Assessed by Transthoracic Echocardiography
Cardiac function will be assessed using transthoracic echocardiography (TTE) performed by an experienced cardiologist. The following echocardiographic parameters will be recorded to evaluate both systolic and diastolic cardiac function: E/A ratio (m/s) e' velocity (cm/s) E/e' ratio Pulmonary vein flow pattern Peak flow velocity (m/s) Left atrial volume index (mL/m²) Left ventricular ejection fraction (LVEF, %) Right atrial volume (mL) Right ventricular volume (mL) Pulse Doppler myocardial performance index (RIMP) Tissue Doppler myocardial performance index (RIMP) Fractional area change (FAC, %) Tricuspid annular plane systolic excursion (TAPSE, cm) Tissue Doppler S wave velocity (cm/s)
Time frame
At baseline (Day 0) and on Day 5 of the studyLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: